2024
2023
2022
2021
2020
2019
Solga AC, Toonen JA, Pan Y, Cimino PJ, Ma Y, Castillon GA, Gianino SM,
Ellisman MH, Lee DY, Gutmann DH. The cell of origin dictates the temporal course
of neurofibromatosis-1 (Nf1) low-grade glioma formation. Oncotarget. 2017 Jul
18;8(29):47206-47215. doi: 10.18632/oncotarget.17589. PubMed PMID: 28525381;
PubMed Central PMCID: PMC5564557.
Houshmandi SS, Emnett RJ, Giovannini M, Gutmann DH: The neurofibromatosis-2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. Mol Cell Biol. 29:1472-86, 2009.
Yeh T-H, Lee DY, Gianino SM, Gutmann DH: Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. GLIA 57:1239-49, 2009.
Yu J, Deshmukh H, Gutmann RJ, Emnett RJ, Rodriguez FJ, Watson MA, Nagarajan R, Gutmann DH: Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology 73:1526-31, 2009.
Hegedus B, Banerjee D, Yeh T-H, Rothermich S, Perry A, Rubin JB, Garbow JR, Gutmann DH: Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res. 68:1520-8, 2008.
Hegedus B, Yeh T-H, Lee DY, Emnett RJ, Li J, Gutmann DH: Neurofibromin regulates somatic growth through the hypothalamic-pituitary axis. Hum Mol Genet. 17:2955-2966, 2008.
Daginakatte GC, Gianino SM, Zhao NW, Parsadanian AS, Gutmann DH: Increased JNK signaling in Neurofibromatosis-1 (Nf1) heterozygous microglia drives microglia activation and promotes optic glioma proliferation. Cancer Res. 68:10358-10366, 2008.
Sharma MK, Mansur DB, Reifenberger G, Perry A, Leonard JR, Aldape KD, Albin MG, Emnett RJ, Loeser S, Watson MA, Nagarajan R, Gutmann DH: Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res. 67:890-900, 2007.
Daginakatte GC, Gutmann DH: Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet. 16:1098-1112, 2007.
Sandsmark DK, Zhang H, Hegedus B, Pelletier CL, Weber JD, Gutmann DH: Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes. Cancer Res. 67:4790-9, 2007.
Hegedus B, Dasgupta B, Shin JE, Emnett RJ, Hart-Mahon EK, Elghazi L, Bernal-Mizrachi E, Gutmann DH: Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. Cell Stem Cell 1:443-457, 2007.
Sharma MK, Watson MA, Lyman M, Perry A, Aldape KD, Deak F, Gutmann DH: Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytoma. Neurology 66:127-130, 2006.
Gerber MA, Bahr SM, Gutmann DH: Protein 4.1B/DAL-1 functions as a growth suppressor in meningioma cells by activating Rac1-dependent JNK signaling. Cancer Res. 66:5295-303, 2006.
Bajenaru ML, Garbow JR, Perry A, Hernandez MR, Gutmann DH: Natural history of neurofibromatosis 1-associated optic nerve glioma formation in mice. Ann Neurol. 57:119-27, 2005.
Dasgupta B, Li W, Perry A, Gutmann DH: Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res. 65:236-45, 2005.
Robb VA, Gerber MA, Hart-Mahon EK, Gutmann DH: Membrane localization of the U2 domain of Protein 4.1B is necessary and sufficient for meningioma growth suppression. Oncogene 24:1946-57, 2005.
Scheidenhelm DK, Cresswell J, Haipek CA, Fleming TP, Mercer RW, Gutmann DH: Akt-dependent cell size regulation by the adhesion molecule on glia (AMOG) occurs independently of phosphotidylinositol 3-kinase and Rheb signaling. Mol Cell Biol. 25:3151-62, 2005.
Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH: Proteomic analysis reveals hyperactivation of the mTOR pathway in NF1-associated human and mouse brain tumors. Cancer Res. 65:2755-60, 2005.
Dasgupta B, Gutmann DH: Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J Neurosci. 25:5584-94, 2005.
Sharma MK, Zehnbauer BA, Watson MA, Gutmann DH: RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology 65:1335-6, 2005.
Surace EI, Haipek CA, Gutmann DH: The effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function. Oncogene 23: 580-7, 2004.
Surace EI, Lusis E, Haipek CA, Gutmann DH: Functional significance of S6K overexpression in meningioma progression. Ann Neurol. 56:295-98, 2004.
Huang Z-y, Wu Y, Burke SP, Gutmann DH: The 43-kDa growth associated protein functions as a negative growth regulator in glioma. Cancer Res. 63:2933-2939, 2003.
Dasgupta B, Dugan LL, Gutmann DH: The neurofibromatosis 1 gene product neurofibromin regulates Pituitary Adenylate Cyclase-Activating Polypeptide-mediated signaling in astrocytes. J Neurosci. 23:8949-54, 2003.
Bajenaru ML, Hernandez MR, Perry A, Zhu Y, Parada LF, Garbow JR, Gutmann DH: Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res. 63: 8573-8577, 2003.
Gutmann DH, Hedrick NM, Li J, Nagarajan R, Perry A, Watson MA. Comparative gene expression profile analysis of neurofibromatosis 1 (NF1)-associated and sporadic pilocytic astrocytomas. Cancer Res. 62:2085-2091, 2002.
Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, Thomas G,Gutmann DH, Giovannini M. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes & Development 16:1060-1065, 2002.
Bajenaru ML, Zhu Y, Hedrick NM, Donahoe J, Parada LF, Gutmann DH. Astrocyte-Specific Inactivation of the Neurofibromatosis 1 gene (NF1) is insufficient for astrocytoma formation. Mol Cell Biol. 22:5100-5113, 2002.
Uhlmann EJ, Wong M, Baldwin RL, Bajenaru ML, Onda H, Kwiatkowski DJ, Yamada K, Gutmann DH. Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol. 52:285-296, 2002.
Bajenaru ML, Donahoe J, Corral T, Reilly KM, Brophy S, Pellicer A, Gutmann DH: Neurofibromatosis 1 (NF1) Heterozygosity results in a cell-autonomous growth advantage for astrocytes. GLIA 33:314-323, 2001.
Li J, Perry A, James CD, Gutmann DH: Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas. Neurology 56:885-890, 2001.
Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, Gutmann DH, Ponta H, Herrlich P: The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes & Development 15:968-980, 2001.
Gutmann DH, Hirbe AC, Haipek CA: Functional analysis of neurofibromatosis 2 (NF2) missense mutations. Hum Mol Genet. 10:1519-1529, 2001.
Gutmann DH, Wu YL, Hedrick NM, Zhu Y, Guha A, Parada LF: Heterozygosity for the neurofibromatosis 1 (NF1) tumor suppressor results in abnormalities in cell attachment, spreading and motility in astrocytes. Hum Mol Genet. 10:3009-3016, 2001.
Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kittiniyom K, Rempel SA, Gutierrez JA, Newsham IF: Loss of DAL-1, a Protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet. 9:1495-1500, 2000.
Gutmann DH, Loehr A, Zhang Y, Kim J, Henkemeyer M and Cashen A: Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene 18:4450-4459, 1999.
Gutmann DH, Geist RT, Xu HM, Kim JS, and Saporito-Irwin S. Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum Mol Genet. 7:335-345, 1998.
Sherman L, Xu HM, Geist RT, Saporito-Irwin S, Howells N, Ponta H, Herrlich P and Gutmann DH: Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 15:2505-2509, 1997.